American Society of Hematology (ASH)
Refine Search
Biotechnology
With Imbruvica (ibrutinib) sales of nearly $10 billion recorded by Janssen and AbbVie combined in 2021, the blood cancer drug has already changed the standard of care for patients in certain settings. 12 December 2022
Biotechnology
Autoimmune diseases specialist argenx has previously referred to Vyvgart (efgartigimod alfa-fcab), an antibody fragment that binds to the neonatal Fc receptor (FcRn), as a ‘pipeline in a product’. 12 December 2022
Biotechnology
At the 2022 American Society of Hematology (ASH) annual meeting, new results for Tecvayli (teclistamab) have been presented by US pharma giant Johnson & Johnson. 12 December 2022
Biotechnology
Roche company Genentech has announced interim results from the Phase III HAVEN 7 study at this year’s American Society of Hematology (ASH) meeting. 12 December 2022
Pharmaceutical
The ASH (American Society of Hematology) Annual Meeting is here once again, ready to round off another year in pharma. 9 December 2022
Biotechnology
Long-suffering investors in bluebird bio had a rare reason for cheer as the company presented positive results for betibeglogene autotemcel (beti-cel) at the American Society of Hematology (ASH) Annual Meeting. 13 December 2021
Biotechnology
US pharma major Bristol Myers Squibb has announced the first disclosure of results from a prespecified interim analysis of the pivotal TRANSFORM study at the American Society of Hematology (ASH) Annual Meeting. 13 December 2021
Biotechnology
Updated results from the ASCEND Phase III trial showed that Calquence (acalabrutinib) maintained a statistically-significant progression-free survival (PFS) benefit at three years compared to investigator’s choice of rituximab combined with either idelalisib (IdR) or bendamustine (BR) in adults with relapsed or refractory chronic lymphocytic leukemia (CLL), the most common type of leukemia in adults, said the drug’s developer, Anglo-Swedish pharma major AstraZeneca 13 December 2021
Pharmaceutical
At the 63rd annual meeting of the American Society of Hematology (ASH), Swiss pharma giant Novartis has announced new positive data for Scemblix (asciminib). 13 December 2021
Biotechnology
Swiss pharma giant Roche has presented new pivotal data on its CD20xCD3 T-cell engaging bispecific antibody, mosunetuzumab, for the first time at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition 2021. 13 December 2021
Pharmaceutical
Virtually every drugmaker with a presence in hematology is preparing for their end-of-year attempt to impress physicians and investors with the best of their freshest data at the American Society of Hematology (ASH) Annual Meeting and Exposition. 10 December 2021
Biotechnology
Fitusiran, an investigational siRNA therapeutic targeting antithrombin for the treatment of hemophilia, has shown its efficacy in late-stage trials. 25 November 2021
Pharmaceutical
Swiss pharma giant Novartis has presented detailed results on its investigational STAMP inhibitor asciminib’s comparison with Pfizer’s (NYSE: PFE) Bosulif (bosutinib) at the 62nd American Society of Hematology Annual Meeting & Exposition (ASH). 8 December 2020
Biotechnology
The Johnson & Johnson subsidiary Janssen has presented new data from the Phase III ANDROMEDA study, which evaluated Darzalex Faspro (daratumumab and hyaluronidase-fihj) as a treatment for patients with light chain (AL) amyloidosis. 8 December 2020
Biotechnology
Dutch gene therapy company uniQure today announced the late-breaking presentation of initial data from its pivotal, Phase III HOPE-B gene therapy trial of etranacogene dezaparvovec, an investigational adeno-associated virus five (AAV5)-based gene therapy for the treatment of patients with severe and moderately severe hemophilia B. 8 December 2020
Biotechnology
US biopharma TG Therapeutics has announced two data sets at the 62nd American Society of Hematology (ASH) Annual Meeting. 7 December 2020
Biotechnology
Gilead Sciences company Kite has announced results from the primary analysis of ZUMA-5, a Phase II study evaluating Yescarta (axicabtagene ciloleucel) in adults with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) after at least two prior lines of therapy. 7 December 2020
Biotechnology
Swiss pharma major Roche has presented a new analysis of three-year follow-up data from the pivotal HAVEN 1-4 studies. 7 December 2020
Biotechnology
Kite today announced follow-up results from the pivotal ZUMA-2 trial of Tecartus (brexucabtagene autoleucel, formerly KTE-X19) in adult patients with relapsed or refractory mantle cell lymphoma (MCL), at the 62nd ASH Annual Meeting and Exposition. 7 December 2020
Biotechnology
New data from the pivotal Phase III MURANO and CLL14 studies support the efficacy of fixed-duration, chemotherapy-free Venclexta/Venclyxto (venetoclax)-based combinations in certain people with chronic lymphocytic leukemia (CLL) and provide more evidence on the potential value of minimal residual disease (MRD). 7 December 2020
Biotechnology
Beam Therapeutics will detail new clinical and preclinical data on its sickle cell disease (SCD) therapies at the upcoming American Society of Hematology (ASH) meeting. 6 November 2024
Biotechnology
Johnson & Johnson unit Janssen has presented the first data from the Phase III PERSEUS study at the annual meeting of the American Society of Hematology (ASH). 13 December 2023
Biotechnology
Kite, a subsidiary of US biotech major Gilead Sciences, has announced the results of new analyses supporting the use of Tecartus (brexucabtagene autoleucel) in relapsed/refractory mantle cell lymphoma (R/R MCL) and relapsed/refractory adult B-cell precursor acute lymphoblastic leukaemia (R/R B-ALL). 12 December 2023
Biotechnology
At the 65th American Society of Hematology (ASH) annual meeting, Gilead Sciences company Kite announced results from a three-year follow-up analysis of the ZUMA-12 trial. 12 December 2023
Pharmaceutical
US pharma major Bristol Myers Squibb has announced the results of two early studies evaluating combinations of CELMoD agent golcadomide in non-Hodgkin lymphomas. 12 December 2023
Biotechnology
Australian biotech CSL Limited has announced the three-year results from the pivotal HOPE-B study confirming continued long-term durability and safety of Hemgenix (etranacogene dezaparvovec-drlb) following a one-time infusion in people living with hemophilia B. 12 December 2023
Biotechnology
The Johnson & Johnson subsidiary Janssen has presented new long-term follow-up data at the 2023 American Society of Hematology (ASH) Annual Meeting from the Phase III GLOW and Phase II CAPTIVATE studies of first-line, fixed-duration treatment with Imbruvica (ibrutinib) plus AbbVie’s enclexta (venetoclax). 11 December 2023
Pharmaceutical
Swiss pharm giant Novartis has announced positive results from the extension period of the pivotal Phase III APPLY-PNH trial of oral monotherapy Fabhalta (iptacopan). 11 December 2023
Biotechnology
Swiss pharma giant Roche has presented new data from its CD20xCD3 T-cell engaging bispecific antibody program at the 65th American Society of Hematology (ASH) Annual Meeting. 11 December 2023
Biotechnology
Adding Sarclisa (isatuximab) to carfilzomib, lenalidomide and dexamethasone (KRd) caused a statistically significant improvement in the rate of minimal residual disease (MRD) negativity, compared with KRd alone, after autologous stem cell transplant (ASCT) consolidation in transplant-eligible patients with newly-diagnosed multiple myeloma (MM). 11 December 2023
Biotechnology
New Jersey, USA-based cancer giant Bristol Myers Squibb has announced positive primary analysis results from the TRANSCEND FL study. 11 December 2023
Pharmaceutical
Britain’s largest drugmaker, AstraZeneca, has announced positive long-term results from the Phase III ALPHA trial at the annual meeting of the American Society of Hematology (ASH). 11 December 2023
Biotechnology
US pharma major Bristol Myers Squibb has presented updated results from the primary analysis of the Phase III COMMANDS trial at the 2023 American Society of Hematology (ASH) Annual Meeting. 10 December 2023
Biotechnology
Findings from the pivotal Phase III BASIS clinical trial evaluating marstacimab for the treatment of people with severe hemophilia A and moderately severe to severe hemophilia B without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) were released at the American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego. 10 December 2023
Biotechnology
At this year’s American Society of Hematology (ASH) Annual Meeting, Swiss pharma giant Roche announced that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra (emicizumab) in previously untreated or minimally treated infants with severe hemophilia A without factor VIII inhibitors. 10 December 2023
Biotechnology
With the end of the year approaching, it is again time for The American Society of Hematology (ASH) Annual Meeting, the last major pharmaceutical conference in the calendar. 9 December 2023
Pharmaceutical
As the 64th annual meeting of the American Society of Hematology (ASH) drew to a close in New Orleans on Tuesday, more clinical updates provided a window into the development prospects for two important programs in this therapy area. 14 December 2022
Biotechnology
US biotech major Regeneron added to its offering at this year’s American Society of Hematology (ASH) meeting with data on linvoseltamab in multiple myeloma. 13 December 2022
Pharmaceutical
Eli Lilly’s (NYSE: LLY) oncology company, Loxo@Lilly, has announced updated clinical data from the global Phase I/II BRUIN trial of pirtobrutinib. 13 December 2022
Biotechnology
USA-based Regeneron Pharmaceuticals has announced positive new and updated data from the Phase I ELM-1 and pivotal Phase II ELM-2 trials of its lymphoma candidate odronextamab. 12 December 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze